Urologix v. ProstaLund
This article was originally published in The Gray Sheet
Executive Summary
Motion for preliminary injunction against sales of ProstaLund's CoreTherm microwave thermotherapy system for benign prostatic hyperplasia is denied by Milwaukee federal court Judge Lynn Adelman, clearing the way for U.S. marketing, pending PMA approval "in the near future," ProstaLund says. Adelman also rules that one of two Urologix patents asserted against ProstaLund is invalid. ACMI will distribute the device...
You may also be interested in...
ProstaLund CoreTherm BPH Device Arrives In U.S., Distributed Through ACMI
ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.